Skip to content

Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers

Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers on the Occurrence of S. Aureus Infections in Hemodialysis Patients

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02945722
Acronym
CIBERSTAPH
Enrollment
434
Registered
2016-10-26
Start date
2018-02-23
Completion date
2024-10-26
Last updated
2024-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis Patients

Keywords

Hemodialysis, S. Aureus, Decolonization, Persistent carriage

Brief summary

S. aureus nasal carriage is a well-known risk factor for S. aureus infections in hemodialysis (HD) patients. Strains of carriage and infections are the same in \>80% of cases We recently shown that persistent carriers of S. aureus, not intermittent ones are at increased risk of staphylococcal infections in HD. Thanks to a new algorithm developped based on one nasal sample the determination of carriage status (persistent, intermittent or non-carriers) among patients is easy. Mupirocin use in HD have been shown to reduce significantly S. aureus infections however, multiples schedules of decolonization have been proposed to all S. aureus carriers. To date, there is no national guideline for decolonization of S. aureus in HD. We showed that only 50% of HD centers in France propose screening and decolonization of S. aureus carriers. The aim of the study is therefore to evaluate the impact of a targeted decolonization of S. aureus persistent carriers using mupirocin nasal ointment and chlorhexidine baths during 5 days on the occurrence of S. aureus infections in HD patients compared to the absence of decolonization using a randomized open study methodology.

Detailed description

Hemodialysis patients will be randomized in 2 arms: one arm where persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers in this arm will be done every 3 months and a new decolonization will be proposed to patients found (again) persistent carriers. Determination of carriage status will be done using one nasal swab by following the algorithm previously described. Bacterial load will be determined by a quantitative S. aureus PCR (Polymerase Chain Reaction) : persistent carriers are the patient with a bacterial load \> 103 CFU/mL (Colony Forming Unit) . The other arm is HD patients in which decolonization is not performed including impersistent carriers. All infections that occurred in enrolled patients will be counted in both groups

Interventions

Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months

OTHERNo decolonization

Screening of persistent carriers in this arm will be done every 3 months

Sponsors

Ministry of Health, France
CollaboratorOTHER_GOV
Centre Hospitalier Universitaire de Saint Etienne
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (age ≥ 18 years-old) * Patient under chronic hemodialysis * Patent that accepted to participate in the study with a written consent form signed

Exclusion criteria

* Patients under peritoneal dialysis * Patients with an active infection at the time of inclusion * Patients previously treated by mupirocin and chlorhexidine for decolonization purpose * Patients that received antimicrobials active on S. aureus during the month before the inclusion * Patients with allergy to mupirocin or chlorhexidine * Patients treated by hemodialysis transiently (non-terminal kidney failure) * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
S. aureus infection12 monthsNumber of S. Aureus define by Centers for Disease Control

Secondary

MeasureTime frameDescription
Bacteremias S. aureus12 monthsImpact of Bacteremias S. aureus
strain of S. aureus12 monthsPercentage of resistants strains of S. aureus at mupirocin and chlorhexidine
persistents carriers of S. aureusMonths : 3, 6, 9, 12Percentage of persistents carriers of S. aureus
endogenous S. aureus infections12 monthssame strain of carriage and infection
non-carriers carriers of S. aureusMonths : 3, 6, 9, 12Percentage of non-carriers carriers of S. aureus
other bacterial infections12 monthsImpact of other bacterial infections without S. aureus
intermittents carriers of S. aureusMonths : 3, 6, 9, 12Percentage of intermittents carriers of S. aureus

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026